VXRT

Vaxart Inc

Add to Watchlist

Advanced Chart

0.000

-0.32(-100.000%)1D

Overview
Forecast
Valuation
Earnings

High

Open

VWAP

Vol

Mkt Cap

118.17M

Low

Amount

EV/EBITDA(TTM)

Total Shares

177.43M

55.82M

EV/OCF(TTM)

P/S(TTM)

1.46

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-3.50M

-123.05%

2.20M

-55.4%

2.03M

-68.23%

Estimates Revision

The market is revising Upward the revenue expectations for Vaxart, Inc. (VXRT) for FY2025, with the revenue forecasts being adjusted by 171.35% over the past three months. During the same period, the stock price has changed by -28.44%.

Revenue Estimates for FY2025

Revise Upward

+171.35%

In Past 3 Month

Stock Price

Go Down

-28.44%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast VXRT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VXRT is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0

Low

4.00

Averages

6.00

High

8.00

Current: 0

Low

4.00

Averages

6.00

High

8.00

B. Riley Securities

Mayank Mamtani

Strong Buy

Maintains

$2.5 → $2

2025-03-27

Reason

B. Riley Securities

Mayank Mamtani

Price Target

$2.5 → $2

2025-03-27

Maintains

Strong Buy

Reason

B. Riley analyst Mayank Mamtani lowered the firm's price target on Vaxart to $2 from $2.50 and keeps a Buy rating on the shares. The Q4 update reaffirmed the mid-2025 top-line data readout timeline for recently initiated ongoing Phase I second generation norovirus program first-in-human study aimed at generating head-to-head superiority over a prior first generation candidate, the analyst tells investors in a research note. The February 21 stop work order issued to BARDA-funded COVID Phase IIb trial results in transitory uncertainty, and somewhat contributes to company's updated cash runway guidance to 4Q25, despite management implementing restructuring plan resulting in a 10% workforce reduction, the firm says.

Oppenheimer

Cheng Li

Buy

Initiates

2024-08-15

Reason

Oppenheimer

Cheng Li

Price Target

2024-08-15

Initiates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Vaxart Inc (VXRT.O) is -1.40, compared to its 5-year average forward P/E of -5.99. For a more detailed relative valuation and DCF analysis to assess Vaxart Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.99

Current PE

-1.40

Overvalued PE

0.93

Undervalued PE

-12.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-19.81

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

58.97

Undervalued EV/EBITDA

-98.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

267.43

Current PS

5.28

Overvalued PS

725.50

Undervalued PS

-190.64